COSCIENS Biopharma Profit Margin

COSCIENS Biopharma (CSCI) currently reports a profit margin of -199.53% as of June 2025. That compares with -67.9% in the prior-year period — down 193.9% year over year. That is below the sector sector average of 19.69%. Use the charts on this page to explore COSCIENS Biopharma's profit margin history and peer comparisons.

COSCIENS Biopharma's profit margin decreased from -67.9% to -199.53% — a 193.9% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

COSCIENS Biopharma's profit margin of -199.53% is lower than the its sector sector average of 19.69%. That is roughly 1113.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but COSCIENS Biopharma's current -199.53% should be judged against industry norms (sector average: 19.69%) and against CSCI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -199.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 19.69%. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following CSCI for alerts when major investors trade the stock.